Last updated on September 2018

An Observational Study of Kadcyla Safety in Breast Cancer

Brief description of study

This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 3,000 patients who are to receive Kadcyla (trastuzumab emtansine). Patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with trastuzumab and a taxane, and administered Kadcyla infusion at physician's discretion will be registered for this surveillance in Korea. Patients will be asked to provide informed consent; data will be collected by electronic Case Report Forms for approximately 6 years.

Clinical Study Identifier: NCT02305641

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: ML29629 ...

Chonnam National University Hwasun Hospital
Jeollanam-do, Korea, Republic of
  Connect »